Blog

  • ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

    Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy. These findings, which stem from the ASCENT-03 trial in triple-negative breast cancer co-led by investigators at Dana-Farber Cancer Institute, are presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. They are also published simultaneously in the New England Journal of Medicine.

    Triple-negative breast cancer (TNBC) accounts for about 15% of all breast cancer cases and is often difficult to treat. The 5-year survival rate for patients with metastatic disease is about 15%. Moreover, around 60% of patients with metastatic TNBC have tumors that lack the molecular marker PD-L1. This absence indicates the tumors will not respond to immune checkpoint inhibitors. For most patients with previously untreated TNBC, chemotherapy is the primary treatment option.

    “There are limited treatment options for patients with advanced triple-negative breast cancer — and that is especially true for those patients whose tumors are PD-L1-negative,” says Dr. Sara Tolaney, chief of the Division of Breast Oncology at Dana-Farber and senior author on the study. “Finding novel treatments that are effective in this patient population is a major priority for the field.”

    Sacituzumab govitecan, an antibody drug conjugate (ADC), targets the protein Trop2, which is present at high levels on the surfaces of TNBC cells. The ADC binds to Trop2 and, through its molecular payload, delivers a potent chemotherapy drug directly to tumor sites. Sacituzumab govitecan is currently approved as a second-line treatment for patients with advanced TNBC. However, roughly half of patients with this disease do not go on to receive a second line of therapy, underscoring the magnitude of the unmet need.

    ASCENT-03, a global, randomized, open-label phase 3 study, evaluates the use of sacituzumab govitecan versus standard chemotherapy as a first-line treatment in patients with locally advanced or unresectable TNBC who are not candidates for immune checkpoint inhibitors. A total of 558 patients across 229 clinical sites in 30 countries were enrolled and randomized to receive either sacituzumab govitecan or chemotherapy. In both treatment groups, about 99% of patients had PD-L1 negative tumors (277 out of 279 for sacituzumab govitecan; 278 out of 279 for chemotherapy).

    After a median follow-up of 13.2 months, patients treated with sacituzumab govitecan were more likely to survive longer without disease progression, with a median progression-free survival of 9.7 months compared to 6.9 months for patients treated with chemotherapy. Those who responded showed a median duration of response of 12.2 months, compared to 7.2 months for those patients who responded to chemotherapy.

    Data on overall survival are immature at this time. The safety profile of sacituzimab govitecan was consistent with its known profile and was manageable with current guidelines and supportive care.

    “As oncologists and investigators, we’re always trying to move more effective therapies into earlier lines of treatment because we want patients to be able to have robust responses that potentially will translate into survival outcomes,” says Tolaney. “The data from ASCENT-03 are very compelling and support sacituzumab govitecan as a potential new standard of care for patients with previously untreated triple-negative breast cancer who are unable to receive immune checkpoint inhibitors.”

    Dana-Farber investigators were involved in the first studies of sacituzumab govitecan in humans and participated in the pivotal clinical trials that led to its initial U.S. Food and Drug Administration approval for patients with pre-treated triple-negative breast cancer. Tolaney also helped lead the TROPiCS-02 study, which led to the ADC’s approval in pre-treated patients with HR-positive, HER2-negative metastatic breast cancer. Earlier this year, Dr. Tolaney presented results of the phase 3 ASCENT-04/KEYNOTE-D19 trial, which showed the combination of sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to current standard treatment in patients with metastatic triple negative breast cancer that tests positive for the immune checkpoint PD-L1.

    Funding: The ASCENT-03 trial was funded by Gilead Sciences, Inc.

    Continue Reading

  • Manx breast cancer survivor urges others ‘not to be scared’

    Manx breast cancer survivor urges others ‘not to be scared’

    Rebecca Brahde and

    Ashlea TraceyIsle of Man

    CHIARA MAZZONE Chiara a woman with short blonde curly hair, there is bunting in the background.CHIARA MAZZONE

    Chiara Mazzone was diagnosed with breast cancer in summer 2023

    A breast cancer survivor has urged others “not to be scared to get checked out”.

    Chiara Mazzone had been attending annual…

    Continue Reading

  • Ex-patient returns to Bristol hospital after swimming success

    Ex-patient returns to Bristol hospital after swimming success

    Chloe HarcombeWest of England

    University Hospitals Bristol and Weston NHS Foundation Trust Three female hospital staff standing with a 15-year-old boy. The women are all in scrubs, two of them in grey and one in light blue. Two of them have their thumbs up while the third is standing with her arms at her side. All of them are looking at the camera and smiling. The boy has short, curly blonde hair and is wearing dark clothing with two medals round his neck. He is holding them, looking at the camera and smiling.University Hospitals Bristol and Weston NHS Foundation Trust

    Ashby returned to Bristol Royal Hospital for Children to celebrate his swimming success

    A teenager who was born with a life-threatening birth defect has…

    Continue Reading

  • Lesser-known symptoms to detect kidney disease and four ways to prevent it, nephrologist explains – The Economic Times

    1. Lesser-known symptoms to detect kidney disease and four ways to prevent it, nephrologist explains  The Economic Times
    2. What you need to know about the stages of chronic kidney disease, according to Mayo Clinic experts  Mayo Clinic Press
    3. The shock…

    Continue Reading

  • Toreros Piece Together Solid Showing at MPSF Open Water

    Toreros Piece Together Solid Showing at MPSF Open Water

    LONG BEACH – Competing in the greater Los Angeles area for the second time in three weeks, the San Diego…

    Continue Reading

  • Can artificial sweeteners affect memory?

    Can artificial sweeteners affect memory?

    Can artificial sweeteners actually be harmful to health? And can consuming them on the regular affect our memory and thinking skills? Although a new link found between sugar alternatives and brain aging requires more study, it may warrant some…

    Continue Reading

  • Assessing Valuation After Strong 21% Monthly Share Price Rally

    Assessing Valuation After Strong 21% Monthly Share Price Rally

    Samsung Electronics (KOSE:A005930) shares have been on a strong run, delivering a 21% gain over the past month with year-to-date returns approaching 83%. Investors are watching closely for hints of what might fuel its next move.

    See our latest analysis for Samsung Electronics.

    After surging nearly 22% in the last month, Samsung Electronics is riding a wave of renewed optimism, with its share price building strong momentum this year. Notably, the 12-month total shareholder return sits at 69%, outperforming many global peers and reinforcing a sense that market confidence in Samsung’s strategy and growth prospects is picking up.

    If Samsung’s run has you thinking about what else could be on the rise, now is the perfect time to discover See the full list for free.

    With shares already up sharply and optimism running high, the big question is whether Samsung is still trading at an attractive value or if the market has already priced in its next chapter of growth. Could this be a real buying opportunity?

    Samsung Electronics’ most popular narrative suggests its shares still trade below a fair value estimate, compared with the most recent close. This sets up a compelling contrast between strong recent returns and the valuation outlook that follows.

    Leadership in advanced semiconductor technologies and high-performance memory is driving customer wins, higher margins, and expanding Samsung’s presence in new and existing markets. Diversification into premium products, AI-powered devices, and high-margin sectors is supporting resilient profitability and reducing revenue cyclicality.

    Read the complete narrative.

    Want to know what bold forecasts are hiding behind this bullish price tag? The narrative hints at strong growth assumptions, shifting margins, and future profits more typical for market leaders. Uncover which aggressive projections are setting the bar for Samsung’s ambitious fair value. Dive into the full narrative to see what could be driving the optimism.

    Result: Fair Value of ₩105,207 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent geopolitical tensions or tougher competition in semiconductors could disrupt Samsung’s stride. This could make the bullish outlook more challenging to achieve.

    Find out about the key risks to this Samsung Electronics narrative.

    While one method suggests Samsung is undervalued, its current price-to-earnings ratio stands at 22.8 times, higher than the peer average of 19.7 times but just below the broader Asian tech industry’s 23.4 times. The fair ratio estimate sits at 31.6 times, hinting there is room to run if the market agrees with optimistic growth assumptions. Are investors willing to pay up, or is caution about competition and future growth starting to creep in?

    See what the numbers say about this price — find out in our valuation breakdown.

    KOSE:A005930 PE Ratio as at Oct 2025

    If you see things differently or want to dig deeper into the numbers, you can build your own Samsung Electronics story in just a few minutes. Do it your way

    A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Samsung Electronics.

    Smart investors always hunt for fresh opportunities before everyone else. Don’t sit on the sidelines when new trends and high-potential stocks could be in your hands.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include 005930.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Microsoft’s new icons are proving surprisingly popular with Apple fans

    Microsoft’s new icons are proving surprisingly popular with Apple fans

    Microsoft officially launched its new Office icons earlier this month to mixed reception, but the divisive designs have impressed one unexpected collective. Thanks to the brand’s swift adoption of the sleek Liquid Glass UI, Apple fans have…

    Continue Reading

  • ‘The wire began to smoke’: how to avoid counterfeits scams on Vinted and other resale sites | E-commerce

    ‘The wire began to smoke’: how to avoid counterfeits scams on Vinted and other resale sites | E-commerce

    When Maheen found a brand-new Dyson Airwrap for the bargain price of £260 on the resale website Vinted, she was thrilled. The seller’s reviews were all five-star, and she trusted in the buyer-protection policy should something go wrong.

    Sold new, an Airwrap costs between £400 and £480, but Maheen did not suspect anything was amiss. “I had used Vinted many times and it was simple and straightforward. Nothing had ever gone wrong,” she says.

    However, after two weeks – and about four uses – she spotted a problem. “I noticed the wire began to smoke and the product seemed unsafe,” she says. Maheen contacted Dyson and was told to send in the Airwrap.

    Its response confirmed her fears. “I got a letter from [Dyson] confirming the product was counterfeit. It was unsafe and they wouldn’t return it to me,” she says.

    Maheen’s experience is far from unique. Almost two-fifths (37%) of Britons have been scammed while buying or selling on online marketplaces such as Facebook Marketplace, eBay and Vinted, according to research from the credit reference agency Experian.

    Victims of this type of crime tend to skew younger, with more than half of gen Z (58%) telling researchers they had been scammed compared with just 16% of people over the age of 55.

    For almost a quarter of people losses were in the region of £51 to £100, while 13% had lost more than £250. A small number said the scam had cost them between £501 and £1,000.

    The most common type of scam respondents encountered – being sent fake or counterfeit products (34%) – is the one Maheen fell prey to. Next up was requests to pay off-platform (31%), and items never arriving after payment (22%).

    What the scam looks like

    It looks like the legitimate item and the description suggests it is – more than half of scam victims (51%) told Experian they only realised they had been scammed once their item was delivered and turned out to be fake, or failed to arrive.

    Photos may be low resolution or look too good – like a catalogue photo – because they have been taken from other websites.

    The price will be less than you would expect and if you start asking questions the seller may try to rush you into a purchase and may ask you to pay them outside the Vinted platform.

    What to do

    Always review a seller’s profile closely and read customer reviews before purchasing an item on a marketplace. Try to obtain as much information about the product as possible before buying – for instance, ask the seller to send a video of the product. To protect yourself, stick to secure payment methods and avoid bank transfers.

    If the worst happens, report the incident to the marketplace and ask for a refund. They may ask for screenshots of messages and the details of the seller or buyer, plus any bank transfer details.

    Maheen was outside the Vinted two-day buyer protection window, but assumed she would get her money back because the product was dangerous. However, she found that it “was really hard to talk to someone”.

    She says: “It felt like I was talking to a bot.”

    With Guardian Money’s help, she has now got her money back.

    A Vinted spokesperson said: “The vast majority of transactions on Vinted take place without issue, and our teams work hard to ensure a smooth trading experience for all our Vinted members.

    “When a dispute does occur between a buyer and a seller, we will mediate, working closely with our delivery partners and potentially asking for additional information or evidence, before issuing a final decision.”

    If appealing to the marketplace directly goes nowhere, there are other things you can do.

    If you used a debit card ask your bank to make a chargeback claim. Alternatively, if you paid by credit card, try a section 75 claim – this is only an option if you have spent more than £100. If you paid by bank transfer it is more complicated, but you may be entitled to a refund under new fraud refund protections.

    Continue Reading